Protara Therapeutics Launches $45M Private Placement Drive
Company Announcements

Protara Therapeutics Launches $45M Private Placement Drive

Protara Therapeutics (TARA) has provided an announcement.

Protara Therapeutics, Inc. has initiated a private placement, selling over 9 million shares of common stock and issuing warrants for additional stock purchase, aiming to raise approximately $45 million. The proceeds are intended for general corporate needs and advancing clinical trials, such as the TARA-002 for Non-Muscle Invasive Bladder Cancer. Accompanying lock-up agreements restrict share transfers by company insiders, while a registration rights agreement demands a resale registration statement to be filed post-closing. This move is part of Protara’s strategy to bolster its financial position and fuel its product development pipeline.

For a thorough assessment of TARA stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyProtara Therapeutics reports Q3 EPS (50c), consensus (52c)
TheFlyProtara Therapeutics sees cash runway into 2026
Christine BrownProtara Therapeutics, Inc. (TARA) Q3 Earnings Cheat Sheet
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App